[Removal of prednisone and prednisolone during plasma exchange]. 1988

U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
Service de Néphrologie, Hôpital Pitié-Salpêtrière, Paris.

Prednisone and prednisolone extraction was determined during seven sessions of plasma exchange in four patients. Each patient received 0.5 mg/kg of prednisone administered orally 2 hours before plasma exchange. Concentrations of prednisone and prednisolone were determined in blood before, every half hour during and at the end of plasma exchange. Both drugs were also determined in removed plasma, mean volume of removed plasma being 0.96 plasmatic mass. The amount of combined prednisone and prednisolone removed by plasma exchange was 1.70% of the administered prednisone dose. This quantity appears minimal and supplemental dosing of prednisone or modification of administration time would seem to be unnecessary.

UI MeSH Term Description Entries
D009135 Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE. Muscle Disorders,Myopathies,Myopathic Conditions,Muscle Disorder,Muscular Disease,Myopathic Condition,Myopathy
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003882 Dermatomyositis A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) Polymyositis-Dermatomyositis,Dermatomyositis, Adult Type,Dermatomyositis, Childhood Type,Dermatopolymyositis,Juvenile Dermatomyositis,Juvenile Myositis,Adult Type Dermatomyositis,Childhood Type Dermatomyositis,Dermatomyositis, Juvenile,Myositis, Juvenile,Polymyositis Dermatomyositis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013577 Syndrome A characteristic symptom complex. Symptom Cluster,Cluster, Symptom,Clusters, Symptom,Symptom Clusters,Syndromes

Related Publications

U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
January 1984, Clinical pharmacy,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
October 1987, Lancet (London, England),
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
January 1987, Biopharmaceutics & drug disposition,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
January 1991, Journal of clinical apheresis,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
January 1987, Journal of clinical apheresis,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
September 1984, Journal of steroid biochemistry,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
January 1957, Hawaii medical journal,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
January 1957, British medical journal,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
February 1956, Revista clinica espanola,
U Assogba, and A Baumelou, and M A Pecquinot, and F Raymond, and J P Durande, and G Lenoir, and J Rottembourg
June 1981, Annals of internal medicine,
Copied contents to your clipboard!